Systematic review of 11 cohort studies (3,980 patients; 8 and 9 meta-analysed): MLH1 promoter hypermethylated endometrial cancers had worse OS (HR 1.34) and PFS (HR 1.33) than other mismatch repair deficient tumours.
Meta-analysisn = 3,980
Lim et al. MLH1 promoter hypermethylated endometrial cancer survival outcomes: A systematic review and meta-analysis